Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 29030 | 3.1704 |
09:34 ET | 10585 | 3.17 |
09:36 ET | 500 | 3.175 |
09:38 ET | 7949 | 3.14 |
09:39 ET | 7396 | 3.14 |
09:41 ET | 10481 | 3.16 |
09:43 ET | 3034 | 3.19 |
09:45 ET | 4562 | 3.19 |
09:48 ET | 1207 | 3.18 |
09:50 ET | 10170 | 3.16 |
09:52 ET | 406 | 3.18 |
09:54 ET | 620 | 3.1711 |
09:56 ET | 13159 | 3.23 |
09:57 ET | 13414 | 3.22 |
09:59 ET | 112119 | 3.25 |
10:01 ET | 10089 | 3.18 |
10:03 ET | 202 | 3.18 |
10:06 ET | 1629 | 3.2 |
10:08 ET | 2250 | 3.18 |
10:10 ET | 10464 | 3.17 |
10:12 ET | 58463 | 3.17 |
10:14 ET | 1700 | 3.1799 |
10:15 ET | 3894 | 3.17 |
10:17 ET | 2358 | 3.17 |
10:19 ET | 5617 | 3.19 |
10:21 ET | 2264 | 3.1831 |
10:24 ET | 5413 | 3.21 |
10:26 ET | 2267 | 3.19 |
10:28 ET | 1755 | 3.2 |
10:30 ET | 1257 | 3.17 |
10:32 ET | 4636 | 3.2 |
10:33 ET | 1610 | 3.22 |
10:35 ET | 1841 | 3.21 |
10:37 ET | 3264 | 3.25 |
10:39 ET | 2403 | 3.245 |
10:42 ET | 3820 | 3.26 |
10:44 ET | 300 | 3.25 |
10:46 ET | 600 | 3.2688 |
10:48 ET | 700 | 3.26 |
10:50 ET | 402 | 3.27 |
10:51 ET | 590 | 3.26 |
10:53 ET | 7293 | 3.28 |
10:55 ET | 1063 | 3.26 |
10:57 ET | 3753 | 3.27 |
11:00 ET | 200 | 3.26 |
11:02 ET | 2600 | 3.245 |
11:04 ET | 2001 | 3.255 |
11:06 ET | 1200 | 3.25 |
11:08 ET | 1078 | 3.27 |
11:09 ET | 100 | 3.26 |
11:11 ET | 1540 | 3.27 |
11:13 ET | 137 | 3.275 |
11:18 ET | 1094 | 3.29 |
11:20 ET | 1345 | 3.2712 |
11:22 ET | 1400 | 3.28 |
11:24 ET | 9900 | 3.27 |
11:27 ET | 2993 | 3.26 |
11:29 ET | 1226 | 3.26 |
11:31 ET | 1500 | 3.27 |
11:33 ET | 4169 | 3.265 |
11:36 ET | 1241 | 3.265 |
11:38 ET | 4776 | 3.26 |
11:40 ET | 2003 | 3.26 |
11:42 ET | 100 | 3.25 |
11:44 ET | 500 | 3.25 |
11:45 ET | 100 | 3.26 |
11:47 ET | 2507 | 3.26 |
11:49 ET | 5653 | 3.25 |
11:54 ET | 1842 | 3.26 |
11:56 ET | 897 | 3.2627 |
11:58 ET | 903 | 3.28 |
12:00 ET | 2815 | 3.2512 |
12:02 ET | 200 | 3.26 |
12:03 ET | 3769 | 3.2614 |
12:05 ET | 2327 | 3.2712 |
12:07 ET | 948 | 3.275 |
12:09 ET | 11459 | 3.25 |
12:12 ET | 1650 | 3.245 |
12:14 ET | 2411 | 3.25 |
12:16 ET | 560 | 3.245 |
12:18 ET | 2149 | 3.265 |
12:20 ET | 1000 | 3.265 |
12:21 ET | 1120 | 3.275 |
12:23 ET | 4591 | 3.29 |
12:25 ET | 1100 | 3.29 |
12:27 ET | 1649 | 3.28 |
12:30 ET | 500 | 3.285 |
12:32 ET | 500 | 3.29 |
12:34 ET | 2818 | 3.2867 |
12:36 ET | 444 | 3.2804 |
12:38 ET | 844 | 3.29 |
12:39 ET | 1111 | 3.29 |
12:41 ET | 500 | 3.295 |
12:43 ET | 200 | 3.295 |
12:45 ET | 1460 | 3.29 |
12:48 ET | 600 | 3.285 |
12:50 ET | 1200 | 3.28 |
12:52 ET | 923 | 3.28 |
12:54 ET | 901 | 3.28 |
12:56 ET | 400 | 3.2772 |
12:57 ET | 200 | 3.28 |
12:59 ET | 600 | 3.285 |
01:01 ET | 1172 | 3.28 |
01:03 ET | 100 | 3.275 |
01:06 ET | 500 | 3.2713 |
01:08 ET | 200 | 3.275 |
01:10 ET | 4169 | 3.28 |
01:12 ET | 200 | 3.2821 |
01:14 ET | 11222 | 3.26 |
01:15 ET | 610 | 3.25 |
01:17 ET | 13584 | 3.2469 |
01:19 ET | 3983 | 3.25 |
01:21 ET | 200 | 3.26 |
01:24 ET | 2037 | 3.26 |
01:26 ET | 1000 | 3.27 |
01:28 ET | 1760 | 3.27 |
01:33 ET | 500 | 3.26 |
01:35 ET | 1186 | 3.26 |
01:37 ET | 3247 | 3.265 |
01:42 ET | 707 | 3.2612 |
01:44 ET | 7804 | 3.28 |
01:46 ET | 5402 | 3.31 |
01:48 ET | 1516 | 3.325 |
01:50 ET | 19061 | 3.33 |
01:51 ET | 450 | 3.31 |
01:53 ET | 1010 | 3.3 |
01:55 ET | 2743 | 3.29 |
01:57 ET | 100 | 3.29 |
02:00 ET | 200 | 3.28 |
02:02 ET | 10200 | 3.28 |
02:04 ET | 1519 | 3.27 |
02:06 ET | 24076 | 3.305 |
02:08 ET | 687 | 3.3085 |
02:09 ET | 300 | 3.305 |
02:11 ET | 2500 | 3.295 |
02:13 ET | 600 | 3.29 |
02:15 ET | 8421 | 3.34 |
02:18 ET | 725 | 3.34 |
02:20 ET | 3964 | 3.345 |
02:22 ET | 9706 | 3.3288 |
02:24 ET | 1700 | 3.315 |
02:26 ET | 18397 | 3.32 |
02:27 ET | 400 | 3.32 |
02:29 ET | 6079 | 3.3 |
02:31 ET | 8784 | 3.305 |
02:33 ET | 10498 | 3.3125 |
02:36 ET | 38568 | 3.355 |
02:38 ET | 65737 | 3.4 |
02:40 ET | 11782 | 3.415 |
02:42 ET | 6428 | 3.42 |
02:44 ET | 14000 | 3.44 |
02:45 ET | 11098 | 3.4 |
02:47 ET | 12160 | 3.41 |
02:49 ET | 13896 | 3.4199 |
02:51 ET | 16631 | 3.39 |
02:54 ET | 528 | 3.39 |
02:56 ET | 2604 | 3.395 |
02:58 ET | 3065 | 3.38 |
03:00 ET | 3209 | 3.38 |
03:02 ET | 15226 | 3.41 |
03:03 ET | 4429 | 3.4 |
03:05 ET | 6210 | 3.4088 |
03:07 ET | 5164 | 3.39 |
03:09 ET | 4680 | 3.39 |
03:12 ET | 3884 | 3.4 |
03:14 ET | 2059 | 3.4 |
03:16 ET | 352 | 3.39 |
03:18 ET | 1748 | 3.4 |
03:20 ET | 2715 | 3.395 |
03:21 ET | 2815 | 3.41 |
03:23 ET | 3330 | 3.4029 |
03:25 ET | 5738 | 3.415 |
03:27 ET | 40037 | 3.43 |
03:30 ET | 1100 | 3.425 |
03:32 ET | 6043 | 3.44 |
03:34 ET | 1825 | 3.44 |
03:36 ET | 4608 | 3.435 |
03:38 ET | 8664 | 3.4488 |
03:39 ET | 2269 | 3.45 |
03:41 ET | 11803 | 3.45 |
03:43 ET | 3786 | 3.45 |
03:45 ET | 46059 | 3.47 |
03:48 ET | 9111 | 3.455 |
03:50 ET | 16514 | 3.4513 |
03:52 ET | 3889 | 3.45 |
03:54 ET | 21309 | 3.475 |
03:56 ET | 53891 | 3.505 |
03:57 ET | 62107 | 3.44 |
03:59 ET | 80865 | 3.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 229.8M | -1.1x | --- |
Rezolute Inc | 229.6M | -4.8x | --- |
Aldeyra Therapeutics Inc | 229.3M | -7.6x | --- |
ATAI Life Sciences NV | 232.7M | -5.8x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.6x | --- |
Pyxis Oncology Inc | 223.8M | -2.9x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.24 |
Book Value | $4.12 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.